The management of refractory carcinoid syndrome: challenges and opportunities ahead

J Med Econ. 2018 Mar;21(3):241-243. doi: 10.1080/13696998.2017.1394312. Epub 2017 Nov 3.
No abstract available

Publication types

  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Humans
  • Malignant Carcinoid Syndrome / drug therapy*
  • Octreotide / therapeutic use
  • Precision Medicine
  • Radiopharmaceuticals / therapeutic use
  • Somatostatin / analogs & derivatives*
  • Somatostatin / economics
  • Time Factors

Substances

  • Radiopharmaceuticals
  • Somatostatin
  • Octreotide